Skip to main content

Emergent BioSolutions to Manufacture Another COVID-19 Vaccine Candidate

Emergent BioSolutions Inc. has received $135M in funding from Johnson & Johnson that will support large-scale manufacturing of J&J’s lead COVID-19 vaccine candidate at their Baltimore City-based manufacturing facility. "Emergent could make up to 300 million doses to advance the vaccine candidate," said Syed Husain, senior vice president, according to the

Read More